Report error Found 3837 Enz. Inhib. hit(s) with Target = 'Serine/threonine-protein kinase Chk1'
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
3D Structure (crystal)
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:AlphaScreen (PerkinElmer Life Sciences, Inc) was performed in opaque 384-well polypropylene plates. The assay relies on hydrogel coated Donor and Acc...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:CHK kinase function was measured in a DELFIA assay in order to monitor phosphorylation of a CDC25C peptide using a specific phospho antibody. The enz...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:CHK kinase function was measured in a DELFIA assay in order to monitor phosphorylation of a CDC25C peptide using a specific phospho antibody. The enz...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:CHK kinase function was measured in a DELFIA assay in order to monitor phosphorylation of a CDC25C peptide using a specific phospho antibody. The enz...More data for this Ligand-Target Pair
Affinity DatapH: 7.5 T: 2°CAssay Description:CHK kinase function was measured in a DELFIA assay in order to monitor phosphorylation of a CDC25C peptide using a specific phospho antibody. The enz...More data for this Ligand-Target Pair
Affinity DataKd: 1.20E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 1.90E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 540nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 1.30E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 1.20E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 3.20nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 300nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataEC50: >1.00E+4nMAssay Description:ChemBL affinity - Published Abbott papersMore data for this Ligand-Target Pair
Affinity DataEC50: 2.20E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 840nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.06E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 280nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.80E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.50E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 2.50E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.20E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 700nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 600nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.30E+4nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 60nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 190nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 150nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 200nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 10nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 8nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 940nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 590nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 40nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 450nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 100nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 60nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 10nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 40nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check pointMore data for this Ligand-Target Pair
